RIGL · Rigel Pharmaceuticals Inc
$42.58
+1.79 (+4.39%)
At close · Aug 14
Market Cap
$795.39M
Shares
18.68M
Rigel Pharmaceuticals Inc Earnings Call Transcripts
Every quarterly earnings call for Rigel Pharmaceuticals Inc (RIGL) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
▲4%
$22.41M
−$19.04M
'22 Q3
22-11-03
▲151.3%
$51.28M
$1.40M
'22 Q4
23-03-07
▲55.8%
$26.07M
−$13.54M
'23 Q1
23-05-02
▼9.8%
$26.89M
−$6.60M
'23 Q2
23-08-01
▲25.5%
$28.13M
−$5.69M
'23 Q3
23-11-07
▼30.2%
$35.79M
$737,000
'23 Q4
24-01-08
▲13.3%
$29.53M
−$8.25M
'24 Q1
24-05-07
▲37%
$36.84M
−$1.03M
'24 Q2
24-08-06
▲96.6%
$55.31M
$12.42M
'24 Q3
24-11-07
▲60.9%
$57.60M
$14.34M
'24 Q4
25-03-04
▲80.6%
$53.33M
$11.45M
'25 Q1
25-05-06
▲176%
$101.69M
$59.61M
'25 Q2
25-08-05
▲25.6%
$69.46M
$27.90M
'25 Q3
25-11-04
▲21.2%
$69.80M
$268.06M
'25 Q4
26-03-03
▲10.3%
$58.82M
$8.65M
'26 Q1
26-05-05
LATEST
▼22.6%
$78.70M
$17.29M
'26 Q2
26-08-04
Capital Markets Day
Investor event
2026-08-13
August 2026 Corporate Presentation
No reported result — non-financial event
Audio
Transcript
Slides
Capital Markets Day
Investor event
2026-08-04
August 2026 Corporate Presentation
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q2
2026-08-04
Rigel Pharmaceuticals Inc Q2 FY2026 Earnings Call
Confident tone
Commercial Launch Execution
Breast Cancer Market Opportunity
Pipeline / R289 Development
Revenue
$78.70M
▼ 22.6% YoY Diluted EPS
$0.88
▼ 73.2% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Capital Markets Day
Investor event
2026-06-16
June 2026 Corporate Presentation
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-06-03
Jefferies Global Healthcare Conference
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-05-12
Rigel Pharmaceuticals, Inc. VEPPANU (vepdegestrant) Licensing Agreement Conference Call
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q1
2026-05-05
Rigel Pharmaceuticals Inc Q1 FY2026 Earnings Call
Confident tone
R289 pipeline in lower-risk MDS
Net product sales growth
2026 financial guidance and profitability
Revenue
$58.82M
▲ 10.3% YoY Diluted EPS
$0.44
▼ 30.2% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-03-03
Rigel Pharmaceuticals Inc Q4 FY2025 Earnings Call
Confident tone
R289 pipeline in lower-risk MDS
Net product sales growth
Commercial product portfolio
Revenue
$69.80M*
▲ 21.2% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-04
Rigel Pharmaceuticals Inc Q3 FY2025 Earnings Call
Confident tone
R289 development in lower-risk MDS
Olutasidenib pipeline expansion
Commercial product sales growth
Revenue
$69.46M
▲ 25.6% YoY Diluted EPS
$1.46
▲ 108.6% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-05
Rigel Pharmaceuticals Inc Q2 FY2025 Earnings Call
Revenue
$101.69M
▲ 176% YoY Diluted EPS
$3.28
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-06
Rigel Pharmaceuticals Inc Q1 FY2025 Earnings Call
Confident tone
R289 pipeline in MDS
Olutasidenib expansion into glioma
Commercial portfolio of three products
Revenue
$53.33M
▲ 80.6% YoY Diluted EPS
$0.63
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-03-04
Rigel Pharmaceuticals Inc Q4 FY2024 Earnings Call
Confident tone
Commercial portfolio growth and product sales
Pipeline development - R289 in lower-risk MDS
Olutasidenib collaborations and IDH1 mutant cancers
Revenue
$57.60M*
▲ 60.9% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-07
Rigel Pharmaceuticals Inc Q3 FY2024 Earnings Call
Confident tone
Commercial growth and product sales
GAVRETO integration and transition
Pipeline development and R289
Revenue
$55.31M
▲ 96.6% YoY Diluted EPS
$0.70
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-06
Rigel Pharmaceuticals Inc Q2 FY2024 Earnings Call
Confident tone
GAVRETO acquisition and launch
R289 pipeline in MDS
TAVALISSE commercial performance
Revenue
$36.84M
▲ 37% YoY Diluted EPS
$-0.06
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-07
Rigel Pharmaceuticals Inc Q1 FY2024 Earnings Call
Confident tone
TAVALISSE demand growth
REZLIDHIA uptake
GAVRETO acquisition
Revenue
$29.53M
▲ 13.3% YoY Diluted EPS
$-0.47
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-01-08
Rigel Pharmaceuticals Inc Q4 FY2023 Earnings Call
Confident tone
GAVRETO acquisition and commercial opportunity
TAVALISSE and REZLIDHIA commercial performance
Market expansion via RET testing and biomarker awareness
Revenue
$35.79M*
▼ 30.2% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-07
Rigel Pharmaceuticals Inc Q3 FY2023 Earnings Call
Revenue
$28.13M
▲ 25.5% YoY Diluted EPS
$-0.33
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-01
Rigel Pharmaceuticals Inc Q2 FY2023 Earnings Call
Revenue
$26.89M
▼ 9.8% YoY Diluted EPS
$-0.38
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-02
Rigel Pharmaceuticals Inc Q1 FY2023 Earnings Call
Revenue
$26.07M
▲ 55.8% YoY Diluted EPS
$-0.80
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-03-07
Rigel Pharmaceuticals Inc Q4 FY2022 Earnings Call
Revenue
$51.28M*
▲ 151.3% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-03
Rigel Pharmaceuticals Inc Q3 FY2022 Earnings Call
Revenue
$22.41M
▲ 4% YoY Diluted EPS
$-1.10
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-02
Rigel Pharmaceuticals Inc Q2 FY2022 Earnings Call
Revenue
$29.82M
▲ 13.5% YoY Diluted EPS
$-0.80
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-03
Rigel Pharmaceuticals Inc Q1 FY2022 Earnings Call
Revenue
$16.73M
▼ 79.3% YoY Diluted EPS
$-1.60
▼ 172.7% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-01-10
Rigel Pharmaceuticals Inc Q4 FY2021 Earnings Call
Revenue
$20.41M*
▲ 10.6% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-11-02
Rigel Pharmaceuticals Inc Q3 FY2021 Earnings Call
Revenue
$21.54M
▲ 17.2% YoY Diluted EPS
$-1.20
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-08-03
Rigel Pharmaceuticals Inc Q2 FY2021 Earnings Call
Revenue
$26.27M
▲ 63.9% YoY Diluted EPS
$-0.80
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-05-05
Rigel Pharmaceuticals Inc Q1 FY2021 Earnings Call
Revenue
$81.02M
▲ 45.3% YoY Diluted EPS
$2.20
▲ 69.2% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-01-11
Rigel Pharmaceuticals Inc Q4 FY2020 Earnings Call
Revenue
$18.45M
▲ 19.8% YoY Gross margin
94.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-11-05
Rigel Pharmaceuticals Inc Q3 FY2020 Earnings Call
Revenue
$18.39M
▼ 11.8% YoY Diluted EPS
$-0.80
Gross margin
87.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-08-04
Rigel Pharmaceuticals Inc Q2 FY2020 Earnings Call
Revenue
$16.02M
▲ 53.9% YoY Diluted EPS
$-1.00
Gross margin
91.7%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-05-05
Rigel Pharmaceuticals Inc Q1 FY2020 Earnings Call
Revenue
$55.76M
▲ 341.7% YoY Diluted EPS
$1.30
Gross margin
22.5%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY19 · Q4
2020-01-13
Rigel Pharmaceuticals Inc Q4 FY2019 Earnings Call
Revenue
$15.40M
▼ 59.3% YoY Gross margin
88.6%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Showing 1–32 of 32 earnings calls
Key facts
CIK
1034842
CUSIP
766559702
13F (30d)
155 filings
152 filers
Visit website
Investor relations